GNLX
Genelux CorporationNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
8.79
P/S
12836.77
EV/EBITDA
-3.03
DCF Value
$0.10
FCF Yield
-25.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-3537.5%
Operating Margin
-415175.0%
Net Margin
-401812.5%
ROE
-153.3%
ROA
-168.9%
ROIC
-251.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $8.0K | $-9.2M | $-0.25 |
| FY 2025 | $8.0K | $-32.1M | $-0.86 |
| Q3 2025 | $0.00 | $-8.0M | $-0.21 |
| Q2 2025 | $0.00 | $-7.5M | $-0.20 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.46
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.